Daniel Hanhart
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Daniel Hanhart has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Panagiotis Chouvardas
University of Bern
4 shared publications George N. Thalmann
Department of Urology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
3 shared publications- Marianna Kruithof-De Julio
University of Bern; Bern University Hospital
3 shared publications - Sofia Karkampouna
Department for BioMedical Research, Urology Research Laboratory, University of Bern, Bern, Switzerland
2 shared publications Andre J van Wijnen
Department of Biochemistry, University of Vermont, Burlington, VT, USA
1 shared publication- Antonio Rodriguez-Calero
Department for BioMedical Research, University of Bern, Bern, Switzerland
1 shared publication
Latest Publications
- Open Access
- 29 May 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
PU.1 is a mediator of the reactive stromal response associated with castration-resistant prostate cancer
Emerging evidence demonstrates the pivotal role played by the tumor microenvironment, particularly cancer-associated fibroblasts, during the development of castration-resistant prostate cancer. In this study, the molecular composition of the tumor microenvironment of androgen-sensitive and castration-resistant metastatic prostate cancer is investigated by utilizing patient-derived xenograft models. Transcriptomic and histological analysis identify the presence of a pro-fibrotic stroma in the castration-resistant (LAPC9) versus the castration-sensitive (PNPCa, BM18) models, characterized by high levels of collagen and tenascin C deposition and upregulation of inflammatory markers. Intra-tumoral collagen- and tenascin-positive stromal areas specifically correlate with higher tumor invasiveness. Master regulator analysis identifies the transcription factor PU.1 as a mediator of the LAPC9 pro-fibrotic phenotype, whose transcriptional activity can be specifically inhibited by the small molecule DB1976. To test the effect of pharmacologic PU.1 inhibition a novel organoid-fibroblast 3D co-culture system, able to mimic features of the in vivo tumor microenvironment, is established. Inhibition of stromal PU.1 activity reverts the pro-fibrotic phenotype and, in turn, reduces tumor organoid growth. Besides identifying a novel molecular player of the pro-fibrotic stromal phenotype in prostate cancer, this study highlights the applicability of 3D tumor organoid-fibroblast co-cultures as in vitro tools to test the effect of stromal-targeting compounds.
- 29 May 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Open AccessPU.1 is a mediator of the reactive stromal response associated with castration-resistant prostate cancer
Emerging evidence demonstrates the pivotal role played by the tumor microenvironment, particularly cancer-associated fibroblasts, during the development of castration-resistant prostate cancer. In this study, the molecular composition of the tumor microenvironment of androgen-sensitive and castration-resistant metastatic prostate cancer is investigated by utilizing patient-derived xenograft models. Transcriptomic and histological analysis identify the presence of a pro-fibrotic stroma in the castration-resistant (LAPC9) versus the castration-sensitive (PNPCa, BM18) models, characterized by high levels of collagen and tenascin C deposition and upregulation of inflammatory markers. Intra-tumoral collagen- and tenascin-positive stromal areas specifically correlate with higher tumor invasiveness. Master regulator analysis identifies the transcription factor PU.1 as a mediator of the LAPC9 pro-fibrotic phenotype, whose transcriptional activity can be specifically inhibited by the small molecule DB1976. To test the effect of pharmacologic PU.1 inhibition a novel organoid-fibroblast 3D co-culture system, able to mimic features of the in vivo tumor microenvironment, is established. Inhibition of stromal PU.1 activity reverts the pro-fibrotic phenotype and, in turn, reduces tumor organoid growth. Besides identifying a novel molecular player of the pro-fibrotic stromal phenotype in prostate cancer, this study highlights the applicability of 3D tumor organoid-fibroblast co-cultures as in vitro tools to test the effect of stromal-targeting compounds.
- Open Access
- 4 March 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-7
ScLinear predicts protein abundance at single-cell resolution
Single-cell multi-omics have transformed biomedical research and present exciting machine learning opportunities. We present scLinear, a linear regression-based approach that predicts single-cell protein abundance based on RNA expression. ScLinear is vastly more efficient than state-of-the-art methodologies, without compromising its accuracy. ScLinear is interpretable and accurately generalizes in unseen single-cell and spatial transcriptomics data. Importantly, we offer a critical view in using complex algorithms ignoring simpler, faster, and more efficient approaches.
- 4 March 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-7
Open AccessScLinear predicts protein abundance at single-cell resolution
Single-cell multi-omics have transformed biomedical research and present exciting machine learning opportunities. We present scLinear, a linear regression-based approach that predicts single-cell protein abundance based on RNA expression. ScLinear is vastly more efficient than state-of-the-art methodologies, without compromising its accuracy. ScLinear is interpretable and accurately generalizes in unseen single-cell and spatial transcriptomics data. Importantly, we offer a critical view in using complex algorithms ignoring simpler, faster, and more efficient approaches.
- Open Access
Molecular profiling of osteoprogenitor cells reveals FOS as a master regulator of bone non-union
- Top Cited PapersOpen Access
- 18 April 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-16
Bladder cancer organoids as a functional system to model different disease stages and therapy response
Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal genetic landscapes, and consistently share key genetic alterations, mirroring tumor evolution in longitudinal sampling. Our drug screening pipeline is implemented using PDOs, testing standard-of-care and FDA-approved compounds for other tumors. Integrative analysis of drug response profiles with matched PDO genomic analysis is used to determine enrichment thresholds for candidate markers of therapy response and resistance. Finally, by assessing the clinical history of longitudinally sampled cases, we can determine whether the disease clonal evolution matched with drug response.
- 18 April 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-16
Top Cited PapersOpen AccessBladder cancer organoids as a functional system to model different disease stages and therapy response
Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal genetic landscapes, and consistently share key genetic alterations, mirroring tumor evolution in longitudinal sampling. Our drug screening pipeline is implemented using PDOs, testing standard-of-care and FDA-approved compounds for other tumors. Integrative analysis of drug response profiles with matched PDO genomic analysis is used to determine enrichment thresholds for candidate markers of therapy response and resistance. Finally, by assessing the clinical history of longitudinally sampled cases, we can determine whether the disease clonal evolution matched with drug response.